@RastogiSonsy @Merck Hi, it looks like your post may have intended to tag another company. Please note our company is Merck in the US and Canada and @MSDInvents elsewhere.
English
MSD
2.1K posts
MSD
@MSDInvents
We aspire to be the premier research-intensive biopharmaceutical company.
Global Beigetreten Ekim 2016
211 Folgt23.7K Follower
@Merck i purchased lodoz 5 batch noM22CH25006 MFD in 11/25 but there is no QR code for checking the genuinity.
Is it allowed to sale?
English
Join us today at 9 a.m. ET to learn more about our Q4 and full-year 2025 #earnings: go.msd.com/~3kr
English
Our Q4 and full-year 2025 #earnings results are live. Check out our full financial summary and key highlights: go.msd.com/~vk8
English
Today, we announced the completion of the acquisition of Cidara Therapeutics, diversifying our pipeline with a novel late-phase antiviral candidate being evaluated for the prevention of symptomatic influenza in certain individuals at high risk of complications. Learn More. msd.gl/4svGbC3
English
Today, we signed a most favored nations agreement with the Trump administration. Addressing global pricing imbalances through a fair, value-based approach is essential, and this agreement helps us do that responsibly, while improving access for U.S. patients at an affordable price. A key component of this agreement is ensuring access to our investigational oral PCSK9 inhibitor being evaluated in patients with elevated cholesterol. Once approved, this medicine will be available through a direct-to-patient program making it easier to get at affordable prices. Over time we hope to be able to broaden access to this important medicine globally at affordable prices. msd.gl/492OKLE
English
We’re excited to share new data from our neuroscience pipeline at CTAD 2025, including results for two #AlzheimersDisease candidates. The U.S. FDA has granted Fast Track Designation to one of our candidates for the treatment of Alzheimer's. Learn more: msd.gl/4q0zeXV
English
Today, we announced an agreement to acquire Cidara Therapeutics, Inc., diversifying our respiratory portfolio to include an investigational long-acting strain-agnostic antiviral agent. msd.gl/49U4Ycb
English
Today, we announced a strategic funding agreement with Blackstone, positioning our company to advance development of an investigational antibody-drug conjugate targeting TROP2 while we continue to advance our broad and expansive pipeline. Read more: msd.gl/4nAqvtG
English
Our Q3 2025 #earnings results are live. Check out our full financial summary and key highlights: msd.gl/3JjUpo1
English
✍️#ColumnaInvitada “La prevención y la educación son clave para mejorar la salud pública”, escribe Edgar Paredes, director de comunicación de
@Merck México.
Léela aquí milenio.com/opinion/varios…
Español
We are pleased to announce that we’ve completed our acquisition of @VeronaPharma, bringing talented new colleagues into our company and strengthening our cardio‑pulmonary footprint. Learn more: msd.gl/3IT5o7E
English
Our Q2 2025 #earnings results are live. Check out our full financial summary and key highlights: msd.gl/40DpkRM
English
Today we announced an agreement to acquire Verona Pharma. Through this acquisition, we will add a novel, important maintenance treatment for chronic obstructive pulmonary disease (#COPD) to strengthen & complement our diversified cardio-pulmonary portfolio msd.gl/4kMGmEh
English
Today, we announced the initiation of our Phase 3 clinical study in #dengue. Learn more: msd.gl/3HFVhSB
English
English
Our Q1 2025 #earnings results are live. Check out our full financial summary and key highlights: msd.gl/3RwURj9
English
Today, we announced an exclusive license to develop, manufacture and commercialize an investigational oral small molecule Lipoprotein(a), or Lp(a), inhibitor from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Learn more: msd.gl/4c1Fh8I
English